Zalman S. Agus, MD; Emeritus Professor, Perelman School of Medicine at the University of Pennsylvania.Action Points BERLIN -- Patients with active psoriatic arthritis -- a group who thus far have had few therapeutic options -- may soon have an additional possibility, ustekinumab (Stelara), an agent already used in psoriasis.Treatment with the interleukin (IL)-12 and IL-23 inhibitor ustekinumab led to 20% improvements in the American College of Rheumatology (ACR20) criteria in 42.4% of
Read more ...
No comments:
Post a Comment